SWOG S2104: Adjuvant CAPTEM for High Risk pNET
SWOG S2104 - Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
CLINICALTRIALS.GOV IDENTIFIER: NCT05040360
DRUG/TREATMENT: Oral treatment; capecitabine and temozolomide
SPONSOR: Southwest Oncology Group (SWOG)
COLLABORATOR: National Cancer Institute (NCI)
Dr. Heloisa Soares Discusses SWOG S2104 Adjuvant CAPTEM for pNET
Dr. Will Pegna Discusses SWOG S2104 Adjuvant CAPTEM for pNET Starting at 4:23
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.
This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.
Heloisa Soares, MD, PhD
Southwest Oncology Group (SWOG)